A scientific and practical center for pharmaceutical development is set to open in the Kirov region. This center will focus on developing vaccines against human papillomavirus and herpes zoster, as reported by the press service of the Russian company Nanolek. The new R&D center will develop and scale up vaccine production technologies, from the active substance to the finished dosage form.
The company is planning to invest 5 billion rubles to boost production capacity and establish new lines at the plant for manufacturing HPV vaccines and other medications.
The primary mission of the center will be to carry out preclinical and clinical research, as well as the subsequent expansion of vaccine manufacturing. The center will be located on an area of 300 square meters and will be equipped with modern equipment for the development and production of a series of vaccines.
The start of a preclinical study of a vaccine to prevent herpes zoster is scheduled for early 2025. The center will operate in accordance with domestic and international standards of efficiency and safety.